Psilocybin for Eating Disorders: Anorexia, Bulimia, and BED

Psilocybin for Eating Disorders: Anorexia, Bulimia, and BED

Eating disorders — anorexia nervosa, bulimia nervosa, and binge eating disorder (BED) — collectively represent some of the most treatment-resistant and deadly psychiatric conditions. Anorexia nervosa has the highest mortality rate of any psychiatric disorder, estimated at 5-10% per decade of illness duration. Conventional treatments (CBT, family-based therapy, nutritional rehabilitation, medications) help many patients, but a significant subset experience chronic relapse and do not achieve long-term recovery. This population represents one of the clearest unmet needs in psychiatry, and it has drawn increasing research attention toward psilocybin-assisted therapy.

The Research Base

Anorexia Nervosa

The landmark study to date is the Imperial College London pilot trial, published in Nature Medicine in 2023:

• Sample: 10 adults with severe, chronic anorexia nervosa (average illness duration: 18 years)
• Design: Open-label, two psilocybin sessions with structured psychological support
• Dose: 25mg synthetic psilocybin per session
• Results: At one month post-second session, 6 of 10 participants showed clinically significant improvements in eating disorder symptoms as measured by the Eating Disorders Examination-Questionnaire (EDE-Q). Improvements persisted at 3-month follow-up in most completers.
• Safety: No serious adverse events. All participants completed the protocol.

The participants in this trial represented a high-severity, treatment-refractory population — people for whom multiple prior treatments had failed. The signal in this population is particularly striking given the typical poor prognosis.

Bulimia Nervosa and Binge Eating Disorder

No published trials specifically target bulimia nervosa or BED with psilocybin as of 2026. However:

• Several academic centers have registered or are designing trials for binge eating disorder, given the substantial overlap in putative mechanisms
• Case reports in the literature and participant accounts describe psilocybin influencing bingeing and purging behaviors through shifts in the cognitive-emotional processing that drives these behaviors
• BED shares significant mechanistic overlap with addiction (reward dysregulation, compulsive behavior despite negative consequences), making it a plausible psilocybin target

Why Psilocybin Might Help Eating Disorders

Rigidity and Cognitive Flexibility

Anorexia in particular is characterized by extreme cognitive rigidity — inflexible beliefs about body, weight, and food that persist despite health consequences. Psilocybin's well-documented effect of increasing cognitive flexibility (reducing cognitive rigidity, allowing new perspectives on fixed beliefs) directly targets this feature. This is the same mechanism proposed for its efficacy in OCD.

The Body Relationship

Many people with eating disorders describe a fundamental disruption in the relationship to their own body — the body experienced as threatening, out of control, or requiring constant management. Participant accounts of psilocybin sessions frequently describe a shift in body experience: from the body as object to the body as experienced subject; from the body as threat to the body as part of a larger, non-threatening whole.

This phenomenological shift — difficult to engineer through conventional therapeutic approaches — appears accessible through psilocybin in some individuals. The Imperial trial investigators specifically noted this as a hypothesized mechanism.

Self-Criticism and Shame

Eating disorders involve severe self-criticism and shame — often more pervasive and intense than the body-image concerns that are the typical clinical focus. Psilocybin's documented reduction in self-criticism (including via the "inner critic quieting" that many participants report in the afterglow period) may address this dimension of eating disorders that CBT often struggles to reach.

Interoceptive Reconnection

Eating disorders frequently involve disrupted interoception — the ability to accurately perceive and respond to internal body signals like hunger, satiety, and emotions. There is preliminary evidence that psilocybin influences interoceptive processing; if this effect includes improved interoceptive accuracy, it could support the reconnection with body signals that recovery from eating disorders requires.

Medical and Safety Considerations

Eating disorders create specific medical vulnerabilities that require careful evaluation before any psilocybin session:

Cardiovascular risk: Anorexia nervosa at low body weight creates significant cardiac risk — arrhythmias, QT prolongation, and orthostatic hypotension. Psilocybin modestly increases heart rate and blood pressure. In medically stable patients at a safe weight, this is manageable; in severely underweight patients with compromised cardiac function, it represents meaningful risk.

Weight thresholds: The Imperial College trial excluded participants below a minimum weight threshold (BMI < 14 kg/m²) specifically because of cardiovascular risk. This is not a barrier to eventual treatment but reflects the need for medical stabilization before psilocybin sessions.

Electrolyte imbalance: Purging behaviors (bulimia) can produce dangerous electrolyte imbalances (hypokalemia, hyponatremia). Electrolytes should be assessed and normalized before any psilocybin session.

Medication interactions: SSRIs are commonly prescribed for bulimia and BED. As with all psilocybin applications, SSRI co-administration blunts psilocybin response; washout considerations require discussion with prescribing physicians.

Body Image in the Session

One concern specific to eating disorders is whether the psilocybin experience might worsen body image distortions — whether heightened perceptual sensitivity combined with existing body image pathology could be destabilizing.

Available evidence suggests this concern, while rational, hasn't been borne out in the limited data:

• The Imperial trial found no worsening of body image distress in any participant
• Participant accounts more commonly describe a softening of body image concerns during and after sessions rather than intensification
• The phenomenological quality of body experience in psilocybin — typically characterized by reduced self-referential processing and increased sense of embodiment — appears to work against the detached, critical relationship to body that characterizes eating disorders

That said, the evidence base is very small. Screening and preparation for session content related to body image should be thorough in any eating disorder population.

Integration Considerations

Integration after psilocybin in eating disorder contexts requires specialized attention:

Relational work: Eating disorders are often deeply relational in origin — connected to family systems, attachment patterns, and identity. Integration may require therapists with eating disorder expertise, not just psychedelic integration training.

Nutritional rehabilitation: Psilocybin does not directly address the nutritional rehabilitation component of anorexia treatment. Integration from psilocybin should occur in the context of ongoing medical and nutritional support.

Slow consolidation: The cognitive rigidity that characterizes anorexia also affects the integration process — fixed beliefs and patterns may be harder to shift through integration practices even when the session opened windows of insight. Patience with a longer integration timeline is often warranted.

Relapse risk: Eating disorders have high relapse rates. Integration should include explicit contingency planning for periods when eating disorder cognitions intensify.

Research Outlook

Eating disorders are increasingly recognized as a high-priority target for psilocybin research. Following the Imperial College pilot, several groups are in the process of Phase 2 trial design. Johns Hopkins has expressed interest in the area, and the scale of unmet need — combined with the mechanistic rationale and early signal — makes expanded research essentially certain.

For people with eating disorders interested in clinical trial participation, clinicaltrials.gov search terms including "psilocybin" + "eating disorder," "anorexia," or "bulimia" will show active registrations as they become available.